I

n a move that should hearten the pharmaceutical industry, the U.S. Supreme Court appears interested in revisiting a contentious legal issue which has the potential to affect lawsuits filed by consumers.

Earlier this week, the court asked the U.S. solicitor general to offer an opinion on a case involving Merck (MRK), which is hoping to dispense hundreds of lawsuits filed more than seven years ago by women who claim they suffered bone fractures after taking Fosamax, a drug used to combat osteoporosis.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.